SuperworthPrelude Therapeutics market cap PRLD
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Oct 23, 2026
- $289.7M
- Highest close in our data
- $3.9B
- Feb 2021
Prelude Therapeutics is worth $289.7M at the close on Oct 23, 2026, at $3.63 a share.
That is up 216% over the last year and down 65% over five years.
Its highest close in our data was $3.9B in Feb 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $289.7M | $113.8M | $529.1M | +88% |
| 2025 | $154M | $37.2M | $154M | +109% |
| 2024 | $73.7M | $44M | $320.8M | −68% |
| 2023 | $234.1M | $99.2M | $389.1M | −19% |
| 2022 | $289.1M | $203.9M | $490.6M | −51% |
| 2021 | $587.8M | $587.8M | $3.9B | −81% |
| 2020 | $3.1B | $2.1B | $3.9B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Prelude Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| PRLDPrelude Therapeutics | $289.7M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| LFVNLifevantage | $73.4M |
| Peer median | $577.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Prelude Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.